U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C25H27NO2
Molecular Weight 373.4874
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 1
Charge 0

SHOW SMILES / InChI
Structure of ENDOXIFEN

SMILES

CC\C(=C(/C1=CC=C(O)C=C1)C2=CC=C(OCCNC)C=C2)C3=CC=CC=C3

InChI

InChIKey=MHJBZVSGOZTKRH-IZHYLOQSSA-N
InChI=1S/C25H27NO2/c1-3-24(19-7-5-4-6-8-19)25(20-9-13-22(27)14-10-20)21-11-15-23(16-12-21)28-18-17-26-2/h4-16,26-27H,3,17-18H2,1-2H3/b25-24-

HIDE SMILES / InChI

Molecular Formula C25H27NO2
Molecular Weight 373.4874
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 1
Optical Activity NONE

Description
Curator's Comment: description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/27346789 https://www.ncbi.nlm.nih.gov/pubmed/21378205

(E)-Endoxifen is the E-isomer of (Z)-Endoxifen, potent selective estrogen receptor modulator. Endoxifen exists as the potently anti-estrogenic (Z)-isomer and the lesser known (E)-isomer. It is assumed that (E)-Endoxifen, structurally related to (E)-4-OH-tamoxifen, have similar pharmacological properties. The (E)-isomer is an impurity in (Z)-Endoxifen drug substance and increases under certain storage conditions. (E)-Endoxifen is identified as the primary degradant.

CNS Activity

Sources: Known to be CNS penetrant in mouse, although P-glycoprotein limits its brain penetration. Human data not available
Curator's Comment: Endoxifen is a P-gp substrate in vitro and in vivo, where P-gp limits its brain penetration.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Unknown

Approved Use

Unknown
Primary
Unknown

Approved Use

Unknown
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
1874 ng/mL
160 mg 1 times / day steady-state, oral
dose: 160 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
ENDOXIFEN plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE
food status: UNKNOWN
635 ng/mL
160 mg single, oral
dose: 160 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
ENDOXIFEN plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE
food status: UNKNOWN
15.1 ng/mL
4 mg single, oral
dose: 4 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
ENDOXIFEN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: FASTED
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
37.9 μg × h/mL
160 mg 1 times / day steady-state, oral
dose: 160 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
ENDOXIFEN plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE
food status: UNKNOWN
9.81 μg × h/mL
160 mg single, oral
dose: 160 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
ENDOXIFEN plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE
food status: UNKNOWN
801 ng × h/mL
4 mg single, oral
dose: 4 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
ENDOXIFEN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: FASTED
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
54.6 h
160 mg single, oral
dose: 160 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
ENDOXIFEN plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE
food status: UNKNOWN
52.1 h
4 mg single, oral
dose: 4 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
ENDOXIFEN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: FASTED
Sourcing

Sourcing

Vendor/AggregatorIDURL
PubMed

PubMed

TitleDatePubMed
Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine.
2003 Dec 3
The tamoxifen metabolite, endoxifen, is a potent antiestrogen that targets estrogen receptor alpha for degradation in breast cancer cells.
2009 Mar 1
Patents

Sample Use Guides

Patients orally administered 4 mg/day or 8 mg/day endoxifen
Route of Administration: Oral
The effects of tamoxifen, and its active metabolite endoxifen on hERG currents stably expressed in HEK cells were investigated using the whole-cell patch-clamp technique and an immunoblot assay. Tamoxifen and endoxifen inhibited hERG tail currents at -50mV in a concentration-dependent manner with IC50 values of 1.2 and 1.6μM, respectively. The steady-state activation curve of the hERG currents was shifted to the hyperpolarizing direction in the presence of endoxifen. The voltage-dependent inhibition of hERG currents by endoxifen increased steeply in the voltage range of channel activation.
Substance Class Chemical
Created
by admin
on Sat Dec 16 05:03:02 UTC 2023
Edited
by admin
on Sat Dec 16 05:03:02 UTC 2023
Record UNII
46AF8680RC
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
ENDOXIFEN
Common Name English
N-DESMETHYL-4-HYDROXYTAMOXIFEN
Common Name English
NSC-749798
Code English
Z-ENDOXIFEN
Common Name English
Endoxifen [WHO-DD]
Common Name English
PHENOL, 4-((1Z)-1-(4-(2-(METHYLAMINO)ETHOXY)PHENYL)-2-PHENYL-1-BUTEN-1-YL)-
Systematic Name English
4-HYDROXY-N-DESMETHYLTAMOXIFEN
Common Name English
Code System Code Type Description
CAS
110025-28-0
Created by admin on Sat Dec 16 05:03:02 UTC 2023 , Edited by admin on Sat Dec 16 05:03:02 UTC 2023
NON-SPECIFIC STEREOCHEMISTRY
EPA CompTox
DTXSID80149880
Created by admin on Sat Dec 16 05:03:02 UTC 2023 , Edited by admin on Sat Dec 16 05:03:02 UTC 2023
PRIMARY
NSC
749798
Created by admin on Sat Dec 16 05:03:02 UTC 2023 , Edited by admin on Sat Dec 16 05:03:02 UTC 2023
PRIMARY
FDA UNII
46AF8680RC
Created by admin on Sat Dec 16 05:03:02 UTC 2023 , Edited by admin on Sat Dec 16 05:03:02 UTC 2023
PRIMARY
SMS_ID
300000041488
Created by admin on Sat Dec 16 05:03:02 UTC 2023 , Edited by admin on Sat Dec 16 05:03:02 UTC 2023
PRIMARY
PUBCHEM
10090750
Created by admin on Sat Dec 16 05:03:02 UTC 2023 , Edited by admin on Sat Dec 16 05:03:02 UTC 2023
PRIMARY
MESH
C055492
Created by admin on Sat Dec 16 05:03:02 UTC 2023 , Edited by admin on Sat Dec 16 05:03:02 UTC 2023
PRIMARY
CAS
112093-28-4
Created by admin on Sat Dec 16 05:03:02 UTC 2023 , Edited by admin on Sat Dec 16 05:03:02 UTC 2023
PRIMARY
WIKIPEDIA
Endoxifen
Created by admin on Sat Dec 16 05:03:02 UTC 2023 , Edited by admin on Sat Dec 16 05:03:02 UTC 2023
PRIMARY
Related Record Type Details
PARENT -> METABOLITE ACTIVE
MAJOR
PLASMA
Related Record Type Details
ACTIVE MOIETY